SCHEMBL16794160

SCHEMBL16794160

Cc1cc(-c2ccnc(N)c2)ccc1CNC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 1/20 0.48
▸ MKNK2 Q9HBH9 1/20 0.48
▸ BTK Q06187 5/20 0.45
▸ CIT O14578 1/20 0.44
▸ ROCK2 O75116 2/20 0.43
▸ KLKB1 P03952 1/20 0.43
▸ WNT3A P56704 1/20 0.43
▸ DYRK1A Q13627 2/20 0.42
▸ GABRP O00591 2/20 0.40
▸ GABRD O14764 2/20 0.40
▸ GABRA1 P14867 2/20 0.40
▸ GABRB1 P18505 2/20 0.40
▸ GABRG2 P18507 2/20 0.40
▸ GABRB3 P28472 2/20 0.40
▸ GABRA5 P31644 2/20 0.40
▸ GABRA3 P34903 2/20 0.40
▸ GABRA2 P47869 2/20 0.40
▸ GABRB2 P47870 2/20 0.40
▸ GABRA4 P48169 2/20 0.40
▸ GABRE P78334 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29676504 0.84 AAK1 (0.48) MKNK1MKNK2BTKCITROCK2
SCHEMBL16794005 0.84 AAK1 (0.48) MKNK1MKNK2BTKCITROCK2
SCHEMBL22659458 0.74 TYK2 (0.47) ABL1NPC1RAB9A
SCHEMBL22659636 0.74 ABL1 (0.48) ABL1
SCHEMBL22659633 0.74 ABL1 (0.48) ABL1
SCHEMBL26655181 0.72 VHL (0.55) BTKWNT3ANPC1RAB9A
SCHEMBL20461079 0.72 BTK (0.64) BTKROCK2ROCK1
SCHEMBL22659496 0.71 HDAC3 (0.39) BTKROCK2KLKB1ROCK1ABL1
SCHEMBL23303990 0.71 MEN1 (0.41) BTKWNT3A
SCHEMBL23304020 0.69 BTK (0.42) BTKKLKB1WNT3ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080103-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY Biogen MA Inc. (US) 2016-10-19 — — EP disclosed
WO-2015089337-A1 BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY BIOGEN IDEC MA INC. (US) 2015-06-18 — — WO disclosed
Send feedback